Medtronic's Recapturable CoreValve Evolut R System Receives CE Mark
Today Medtronic, Inc. (NYSE: MDT) reported that its next generation of the CoreValve transcatheter aortic valve has received the CE Mark and is now available in Europe and other countries that recognize the CE Mark. This new system offers greater accuracy, better fit, the ability to recapture and reposition the valve during deployment, and has the smallest sheath size (14F) curently availabe on the market. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - September 3, 2014 Category: Cardiology Source Type: news
Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference
Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Morgan Stanley Global Healthcare Conference, September 8, 2014, in New York. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 3:25 p.m. EDT (2:25 p.m. CDT). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - September 2, 2014 Category: Cardiology Source Type: news
Volcano Corporation Presentation At Morgan Stanley Conference To Be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Morgan Stanley Healthcare conference on Tuesday, September 9. The presentation by Scott Huennekens, president and chief executive officer, will begin at 11:10 a.m., Eastern Daylight Time (8:10 a.m., Pacific Daylight Time). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - September 2, 2014 Category: Cardiology Source Type: news
Access to Abbott's MitraClip® System Expands in the U.S. with Medicare National Coverage Determination
The Centers for Medicare & Medicaid Services (CMS) recently issued a National Coverage Determination (NCD) that extends coverage for Medicare beneficiaries in the United States to Transcatheter Mitral Valve Repair with Abbott's (NYSE: ABT) MitraClip® System. The MitraClip System is a first-of-its-kind device that provides new hope for people with severe degenerative mitral regurgitation who are not good candidates for surgery. Treatment with MitraClip can significantly improve symptoms and quality of life by reducing the backward flow of blood through the mitral valve in the heart.U (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 13, 2014 Category: Cardiology Source Type: news
Volcano Reports Second Quarter Results
Volcano Corporation (Nasdaq: VOLC) today reported results for the second quarter and first six months of 2014. The company also announced today that it will be seeking a divestiture of its Axsun Technologies, Inc. subsidiary. In addition, the company said that it and St. Jude Medical, Inc., (NYSE: STJ) have agreed to settle all existing litigation between the two companies. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 9, 2014 Category: Cardiology Source Type: news
Study Published in The New England Journal of Medicine Finds Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation in Stroke Patients Better Than Standard Care
Medtronic, Inc. (NYSE: MDT), today announced results from the CRYSTAL AF (CRYptogenic STroke And underLying Atrial Fibrillation) Clinical Trial have been published in The New England Journal of Medicine. The Trial found that continuous cardiac monitoring with the Reveal® XT Insertable Cardiac Monitor (ICM) was superior to standard care at detecting atrial fibrillation (AF) in patients who have had strokes of undetermined causes (cryptogenic stroke). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 26, 2014 Category: Cardiology Source Type: news
Edwards Lifesciences Launching Sapien XT Valve In The U.S.
Edwards Lifesciences Corporation (NYSE: EW) today announced that it has received United States Food and Drug Administration (FDA) approval for its Edwards SAPIEN XT transcatheter aortic heart valve for the treatment of high-risk and inoperable patients suffering from severe symptomatic aortic stenosis (AS). This next-generation, lower-profile system, which includes the 29mm valve size for patients with a large native annulus, will allow for the treatment of more patients. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 16, 2014 Category: Cardiology Source Type: news
Medtronic CoreValve System Receives FDA Approval for Patients at High Risk for Surgery
Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve® System for patients with severe aortic stenosis who are at high risk for surgery.This approval is based on groundbreaking research that showed clinical outcomes at one year with the CoreValve System were superior to open-heart surgery, the current gold standard for aortic valve replacement. The FDA approved the CoreValve System without the need for an independent device advisory panel review due to its exceptionally positive clinical results demonstrated in the High Risk Study of ...
Source: News from Angioplasty.Org - June 14, 2014 Category: Cardiology Source Type: news
Volcano Corporation Schedules Conference Call, Webcast To Discuss iFR® Technology Market Opportunity
Volcano Corporation (Nasdaq: VOLC) said today that it will be holding a conference call and webcast to discuss the market expansion opportunity for its iFR (instant wave-Free Ratio™) technology on Thursday, June 5. The presentation by John Dahldorf, chief financial officer, and Joseph Burnett, executive vice president, coronary and systems business unit, will begin at 1:30 p.m., Pacific Daylight Time (4:30 Eastern Daylight Time). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 5, 2014 Category: Cardiology Source Type: news
Volcano Corporation Presentation At Goldman Sachs Healthcare Conference To Be Webcast
Volcano Corporation (Nasdaq: VOLC), a platform company providing and guiding minimally invasive therapies utilizing visualization, physiology or future technologies, said today that it will be participating in the Goldman Sachs 35th Annual Global Healthcare Conference on Tuesday, June 10. The presentation by John Dahldorf, chief financial officer, will begin at 11:20 a.m., Pacific Daylight Time (2:20 p.m., Eastern Daylight Time) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 5, 2014 Category: Cardiology Source Type: news
Volcano Corporation Announces Agreement To Acquire AtheroMed
Volcano Corporation (Nasdaq: VOLC) said today it has signed an agreement to acquire AtheroMed, Inc., a privately-held company that has developed the Phoenix® Atherectomy System used in the treatment of peripheral artery disease (PAD). The Phoenix, which received 510(k) clearance in January 2014 and has a CE Mark, enables physicians to treat PAD with a low profile peripheral atherectomy catheter that continuously removes diseased material as it is debulked. The device has reimbursement in the U.S. and select countries in Europe. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 5, 2014 Category: Cardiology Source Type: news
Volcano Corporation Presentation At Bank Of America Merrill Lynch 2014 Health Care Conference To Be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13. The presentation by John Dahldorf, chief financial officer, will begin at 4:20 p.m., Pacific Daylight Time (7:20 p.m., Eastern Daylight Time). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 9, 2014 Category: Cardiology Source Type: news
Abbott's MitraClip Approved in Canada
Abbott (NYSE: ABT) has announced that its MitraClip Delivery System has been approved in Canada for use in patients "with degenerative mitral regurgitation who are too high risk for mitral valve surgery based on evaluation by a team of heart doctors, including a heart surgeon." The ruling by Health Canada now allows sale of the MitraClip throughout the country; the MitraClip was approved by the FDA for use in the United States last October. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 5, 2014 Category: Cardiology Source Type: news
Volcano Reports First Quarter Results
Volcano Corporation (Nasdaq: VOLC) today reported results for the first quarter of 2014. For the quarter ended March 31, 2014, Volcano reported revenues of $94.5 million versus revenues of $93.2 million in the same period a year ago. On a constant currency basis, revenues increased four percent year-over-year after adjusting for a negative impact of approximately $2.7 million from foreign currency. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 2, 2014 Category: Cardiology Source Type: news
Volcano Announces Limited Market Release of SyncVision™ Technology System
Volcano Corporation (NASDAQ: VOLC) today announced the commencement of its limited market release of its FDA cleared and CE marked technology SyncVision™, with cases being performed in the U.S. and Europe. SyncVision™ is currently installed in multiple limited market release sites throughout U.S. and Europe. Volcano's SyncVision™ Technology System is an on-line image processing workstation for coronary catheterizations that allows the physician to navigate simultaneously on an angiogram and on an IVUS image in a single correlated view using co-registration of the Eagle Eye® Platinum catheter with x-ray angiography. ...
Source: News from Angioplasty.Org - April 25, 2014 Category: Cardiology Source Type: news
